The United Kingdom and the United States have secured a important trade agreement that will guarantee zero levies on UK drug exports entering the US market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has committed to raise funding on pharmaceuticals through the NHS. This move ensures that tariffs on these crucial products will remain at nothing for a period of 36 months.
This agreement comes after earlier warnings to significantly raise duties on patented pharmaceutical products, with figures discussed as high as double the cost.
"This arrangement between the United Kingdom reinforces the global environment for new treatments and establishes much-needed fairness to transatlantic pharmaceutical trade," a release noted.
Economic Importance
Pharmaceuticals constitute one of the the United Kingdom's biggest export categories to the America, which is by far the biggest market for major companies like GSK and AstraZeneca.
Export figures show that in the year prior to the third quarter, the UK exported drugs worth £11.1bn to the US. This figure accounted for nearly one-fifth of British export trade in that timeframe.
"This deal protects jobs, increases investment and paves the way for the UK to emerge as a worldwide center for medical research," a government official remarked.
Detailed British Pledges
The pact entails several specific pledges from the British government:
- Price Threshold Increase: The UK will raise the cost ceiling at which it judges new treatments to be too expensive by 25%.
- Increased NHS Spending: There is a target to raise total public funding on treatments from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum drug companies must pay back to the NHS to control costs will be limited at 15%. Previously, refunds were more than twenty percent.
Industry Background
This agreement takes place against a long-running tension between the drug companies and the British authorities over medicine costs and NHS adoption.
This friction were exacerbated by assertions that US consumers were charged several times more for the same drugs than patients in the UK and Europe.
Recently, several large manufacturing plans in the UK have been paused or cancelled, while substantial investments have been pledged toward US facilities.
The Science Minister publicly accepted that the NHS had to spend more on medicines, noting that its budget allocation on drugs had declined as a share of its resources over the last ten years.
